Author

Severine Vermeire

EFFECTS OF SUBCUTANEOUS VEDOLIZUMAB ON HEALTH-RELATED QUALITY OF LIFE AND WORK PRODUCTIVITY IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM THE PHASE 3 VISIBLE 2 TRIAL
EFFECTS OF SUBCUTANEOUS VEDOLIZUMAB ON HEALTH-RELATED QUALITY OF LIFE AND WORK PRODUCTIVITY IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM THE PHASE 3 VISIBLE 2 TRIAL

Severine Vermeire  et al.

INTESTINAL EXPRESSION OF THE SARS-COV-2 RECEPTOR ACE2 AND TMPRSS2 IN BIOPSIES AND DERIVED ORGANOIDS FROM PATIENTS WITH INFLAMMATORY BOWEL DISEASE
INTESTINAL EXPRESSION OF THE SARS-COV-2 RECEPTOR ACE2 AND TMPRSS2 IN BIOPSIES AND DERIVED ORGANOIDS FROM PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Severine Vermeire  et al.

EARLY ACHIEVEMENT OF PARTIAL MAYO SCORE REMISSION AND IBDQ NORMALIZATION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH FILGOTINIB IN THE PHASE 2B/3 SELECTION STUDY
EARLY ACHIEVEMENT OF PARTIAL MAYO SCORE REMISSION AND IBDQ NORMALIZATION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH FILGOTINIB IN THE PHASE 2B/3 SELECTION STUDY

Severine Vermeire  et al.

COVID19 VACCINATION COVERAGE IN FLEMISH PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES
COVID19 VACCINATION COVERAGE IN FLEMISH PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES

Severine Vermeire  et al.

EFFECTIVENESS OF USTEKINUMAB AS INDUCTION THERAPY FOR CHRONIC ANTIBIOTIC REFRACTORY POUCHITIS
EFFECTIVENESS OF USTEKINUMAB AS INDUCTION THERAPY FOR CHRONIC ANTIBIOTIC REFRACTORY POUCHITIS

Severine Vermeire  et al.

VEDOLIZUMAB LONG-TERM TREATMENT PERSISTENCE AND SAFETY – RESULTS FROM A MULTINATIONAL EXTENDED ACCESS PROGRAMME STUDY
VEDOLIZUMAB LONG-TERM TREATMENT PERSISTENCE AND SAFETY – RESULTS FROM A MULTINATIONAL EXTENDED ACCESS PROGRAMME STUDY

Severine Vermeire  et al.

LONG-TERM UPREGULATION OF MIR-124 IN BLOOD AND RECTAL BIOPSIES OF PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS RECEIVING OBEFAZIMOD 50 MG DAILY FOR 96-WEEKS
LONG-TERM UPREGULATION OF MIR-124 IN BLOOD AND RECTAL BIOPSIES OF PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS RECEIVING OBEFAZIMOD 50 MG DAILY FOR 96-WEEKS

Severine Vermeire  et al.

CORRELATION OF MIR-124 UPREGULATION AND PK PARAMETERS IN BLOOD OF PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS RECEIVING OBEFAZIMOD FOR 16 WEEKS
CORRELATION OF MIR-124 UPREGULATION AND PK PARAMETERS IN BLOOD OF PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS RECEIVING OBEFAZIMOD FOR 16 WEEKS

Severine Vermeire  et al.

MICROBIOME DYSBIOSIS, INTESTINAL EPITHELIAL CELL DYSFUNCTION AND IMMUNE SYSTEM DEREGULATION IN PATIENTS WITH CROHN'S DISEASE
MICROBIOME DYSBIOSIS, INTESTINAL EPITHELIAL CELL DYSFUNCTION AND IMMUNE SYSTEM DEREGULATION IN PATIENTS WITH CROHN'S DISEASE

Severine Vermeire  et al.

PROLONGED BENEFIT OF FILGOTINIB IN PATIENTS WITH ULCERATIVE COLITIS IN SELECTION
PROLONGED BENEFIT OF FILGOTINIB IN PATIENTS WITH ULCERATIVE COLITIS IN SELECTION

Severine Vermeire  et al.

AN AUTOMATED SYSTEM FOR ESTIMATION OF HISTOLOGICAL DISEASE ACTIVITY IN ULCERATIVE COLITIS: COMPARISON OF PERFORMANCES WITH WHITE LIGHT VERSUS SINGLE WAVELENGTH ENDOSCOPY
AN AUTOMATED SYSTEM FOR ESTIMATION OF HISTOLOGICAL DISEASE ACTIVITY IN ULCERATIVE COLITIS: COMPARISON OF PERFORMANCES WITH WHITE LIGHT VERSUS SINGLE WAVELENGTH ENDOSCOPY

Severine Vermeire  et al.

POTENTIAL OF HIGH-ACETATE PRODUCING SACCHAROMYCES BOULARDII TO ATTENUATE INFLAMMATION IN DSS-INDUCED COLITIS
POTENTIAL OF HIGH-ACETATE PRODUCING SACCHAROMYCES BOULARDII TO ATTENUATE INFLAMMATION IN DSS-INDUCED COLITIS

Severine Vermeire  et al.

EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS RECEIVING 16 WEEKS’ EXTENDED INDUCTION TREATMENT FOLLOWED BY 52 WEEKS’ MAINTENANCE TREATMENT IN THE U-ACHIEVE/U-ACCOMPLISH TRIALS
EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS RECEIVING 16 WEEKS’ EXTENDED INDUCTION TREATMENT FOLLOWED BY 52 WEEKS’ MAINTENANCE TREATMENT IN THE U-ACHIEVE/U-ACCOMPLISH TRIALS

Severine Vermeire  et al.

UPADACITINIB TREATMENT IMPROVES HEALTH-RELATED QUALITY OF LIFE AMONG PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 INDUCTION STUDIES U-ACHIEVE AND U-ACCOMPLISH
UPADACITINIB TREATMENT IMPROVES HEALTH-RELATED QUALITY OF LIFE AMONG PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 INDUCTION STUDIES U-ACHIEVE AND U-ACCOMPLISH

Severine Vermeire  et al.

TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 9.2 YEARS OF SAFETY DATA FROM THE GLOBAL CLINICAL PROGRAMME
TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 9.2 YEARS OF SAFETY DATA FROM THE GLOBAL CLINICAL PROGRAMME

Severine Vermeire  et al.

RAPIDITY OF SYMPTOM CONTROL WITH UPADACITINIB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM TWO RANDOMIZED PHASE 3 STUDIES
RAPIDITY OF SYMPTOM CONTROL WITH UPADACITINIB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM TWO RANDOMIZED PHASE 3 STUDIES

Severine Vermeire  et al.

SCORING OF HISTOLOGICAL REMISSION IN ULCERATIVE COLITIS BASED ON AUTOMATED COMPUTER-AIDED ANALYSIS OF ENDOSCOPIC IMAGES OUTPERFORMS HUMAN SCORING
SCORING OF HISTOLOGICAL REMISSION IN ULCERATIVE COLITIS BASED ON AUTOMATED COMPUTER-AIDED ANALYSIS OF ENDOSCOPIC IMAGES OUTPERFORMS HUMAN SCORING

Severine Vermeire  et al.

TWO-YEAR EFFICACY AND SAFETY OF MIRIKIZUMAB FOLLOWING 104 WEEKS OF CONTINUOUS TREATMENT: INTERIM RESULTS FROM THE LUCENT-3 OPEN-LABEL EXTENSION STUDY
TWO-YEAR EFFICACY AND SAFETY OF MIRIKIZUMAB FOLLOWING 104 WEEKS OF CONTINUOUS TREATMENT: INTERIM RESULTS FROM THE LUCENT-3 OPEN-LABEL EXTENSION STUDY

Severine Vermeire  et al.

HIGHER ENDOSCOPIC AND CLINICAL REMISSION RATES WITH VEDOLIZUMAB IN EARLY THAN IN LATE CROHN’S DISEASE: RESULTS FROM THE LOVE-CD STUDY (LOW COUNTRIES VEDOLIZUMAB IN CD STUDY)
HIGHER ENDOSCOPIC AND CLINICAL REMISSION RATES WITH VEDOLIZUMAB IN EARLY THAN IN LATE CROHN’S DISEASE: RESULTS FROM THE LOVE-CD STUDY (LOW COUNTRIES VEDOLIZUMAB IN CD STUDY)

Severine Vermeire  et al.

COMPREHENSIVE CHARACTERIZATION OF THE EXPOSURE-RESPONSE RELATIONSHIP OF VEDOLIZUMAB IN ULCERATIVE COLITIS: RESULTS FROM THE LOVE-UC STUDY
COMPREHENSIVE CHARACTERIZATION OF THE EXPOSURE-RESPONSE RELATIONSHIP OF VEDOLIZUMAB IN ULCERATIVE COLITIS: RESULTS FROM THE LOVE-UC STUDY

Severine Vermeire  et al.

Item 81 - 100 / 107
1 2 3 4
5
6